AACR logo

More articles from Article

Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
Masaaki Komatsu, Keiko Hiyama, Keiji Tanimoto, Mayu Yunokawa, Keiko Otani, Megu Ohtaki, Eiso Hiyama, Junzo Kigawa, Michitaka Ohwada, Mitsuaki Suzuki, Nobutaka Nagai, Yoshiki Kudo, Masahiko Nishiyama

Molecular Cancer Therapeutics Mar 2006, 5 (3) 767-775; DOI: 10.1158/1535-7163.MCT-05-0408
Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
Elvira Crescenzi, Angela Chiaviello, Gianfranco Canti, Elena Reddi, Bianca Maria Veneziani, Giuseppe Palumbo

Molecular Cancer Therapeutics Mar 2006, 5 (3) 776-785; DOI: 10.1158/1535-7163.MCT-05-0425
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Ruoping Tang, Anne-Marie Faussat, Patricia Majdak, Christophe Marzac, Sabine Dubrulle, Zora Marjanovic, Ollivier Legrand, Jean-Pierre Marie

Molecular Cancer Therapeutics Mar 2006, 5 (3) 723-731; DOI: 10.1158/1535-7163.MCT-05-0164
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O⁶-benzylguanine
Tomio Ueno, Sae Hee Ko, Elizabeth Grubbs, Yasunori Yoshimoto, Christi Augustine, Zeinab Abdel-Wahab, Tsung-Yen Cheng, Omar I. Abdel-Wahab, Scott K. Pruitt, Henry S. Friedman, Douglas S. Tyler

Molecular Cancer Therapeutics Mar 2006, 5 (3) 732-738; DOI: 10.1158/1535-7163.MCT-05-0098
Identification of a small topoisomerase I–binding peptide that has synergistic antitumor activity with 9-aminocamptothecin
Christopher D. Pond, Kathryn M. Marshall, Louis R. Barrows

Molecular Cancer Therapeutics Mar 2006, 5 (3) 739-745; DOI: 10.1158/1535-7163.MCT-05-0377
Sulindac independently modulates extracellular signal–regulated kinase 1/2 and cyclic GMP–dependent protein kinase signaling pathways
Pamela L. Rice, Stevany L. Peters, K. Scott Beard, Dennis J. Ahnen

Molecular Cancer Therapeutics Mar 2006, 5 (3) 746-754; DOI: 10.1158/1535-7163.MCT-05-0210
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Svetlana Komarova, Yosuke Kawakami, Mariam A. Stoff-Khalili, David T. Curiel, Larisa Pereboeva

Molecular Cancer Therapeutics Mar 2006, 5 (3) 755-766; DOI: 10.1158/1535-7163.MCT-05-0334
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
Jordi Codony-Servat, Maria A. Tapia, Marta Bosch, Cristina Oliva, Josep Domingo-Domenech, Begoña Mellado, Mark Rolfe, Jeffrey S. Ross, Pere Gascon, Ana Rovira, Joan Albanell

Molecular Cancer Therapeutics Mar 2006, 5 (3) 665-675; DOI: 10.1158/1535-7163.MCT-05-0147
Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene
Xiong Li, Sudhanshu P. Raikwar, You-Hong Liu, Sang-Jin Lee, Yan-Ping Zhang, Shaobo Zhang, Liang Cheng, Sang-Don Lee, Beth Elisa Juliar, Thomas A. Gardner, Meei-Huey Jeng, Chinghai Kao

Molecular Cancer Therapeutics Mar 2006, 5 (3) 676-684; DOI: 10.1158/1535-7163.MCT-05-0339
The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor–positive and estrogen receptor–negative human breast cancers
Heekyoung Chung, Ji-Youn Jung, Sung-Dae Cho, Kyung-A Hong, Hyun-Jun Kim, Dong-Hui Shin, Hwan Kim, Hea Ok Kim, Dae Hong Shin, Hyuk Woo Lee, Lak Shin Jeong, Gu Kong

Molecular Cancer Therapeutics Mar 2006, 5 (3) 685-692; DOI: 10.1158/1535-7163.MCT-05-0245

Main menu

User menu

Search

More articles from Article

Pages

Articles

Info for

About MCT